7th Congress of the European Society for Clinical
May 5-9 2004
This volume represents the proceedings of the 7th Congress of the ESCNP,
held in Trieste, Italy, May 5-9, 2004 and contains both invited lectures
and free communications presented there.
Clinical neuropharmacology is the part of the neurosciences that brings
together clinicians and basic scientists with the purpose of discovering
and describing new knowledge in the diagnostic and therapeutical
approach to the diseases of the nervous system.
Clinical neuropharmacology has had an impressive development during the
past decades in parallel with the increasing of our knowledge on the
basic mechanisms of function and metabolism of the CNS in normal and
pathological conditions; particularly, the great development of
molecular biology as well as of the new technologies of functional
imaging in man, such as PET, SPECT, and MR spectroscopy, has allowed
great advances in the understanding of some main mechanisms of diseases
in man and therefore in the searching for new drugs for their treatment.
The 7th Congress of the ESCNP has focused the attention on some very
important issues of clinical and basic neurosciences, in which there
have been quite relevant advancements in the recent years; these are
post-stroke management, Alzheimer’s dementia, multiple sclerosis,
Parkinson’s disease, epilepsy; furthermore, the repair mechanisms in the
nervous system and the relationship between neurorehabilitation and
neuropharmacology, as well as psychiatric disorders in CNS diseases.
Clinical neuropharmacology has certainly a great future in the field of
basic and clinical sciences devoted to the diseases of the nervous
system but also in the one of designing better ways to transfer our
knowledge into the clinical practice, that is modern and efficacious
guidelines to get new therapies available for the best of the patients.
The interdisciplinary approach to such arguments is really the only way
to provide a true advancement of our knowledge in these fields; it is
our hope that the efforts made in this direction will be really useful
to the purpose of getting better therapeutical approaches to the
diseases of the nervous system.
Adjuvant Therapy in Rehabilitation of Post-stroke Aphasia
W.-D. Heiss, A. Thiel, L. Winhuisen, B. Mühlberger, J. Kessler and K.
Cerebral Stroke (CI) and Management of Arterial Hypertension Where We Are
and Where We Want To Be?
D. Bartko, A. Dukat, M. Zigrai and V. Vestenicka
Could New Antihypertensive and Lipid Lowering Drugs Prevent Second Stroke?
Plasticity and Recovery After Stroke
Diagnosis and Differential Diagnosis of Dementia
Improvement of Verbal Fluency in Alzheimer’s Disease After NADH Treatment
V. Demarin, D. Storga-Tomić, M. Bosnar-Puretić,
I. Martinić-Popović and J. Birkmayer
A Neuropsychological Comparison Between Subcortical Vascular Dementia and
Frontal Lobe Dementia
R. Moretti, P. Torre, R.M. Antonello, G. Cazzato and A. Bava
A Placebo-controlled Study of Memantine in Dementia of Wernicke-Korsakoff
Syndrome, Alzheimer’s Disease, and Vascular Dementia
A. Rustembegović, E. Sofic, Z. Kundurovic, I. Tahirović and A. Sapcanin
A Cellular Model of Dopamine-Dependent Cell Toxicity in Parkinson’s
M. Colapinto, M. Molteni, S. Giraudo, M. Basso, C. Rossetti, D. Marabella,
B. Bergamasco, L. Lopiano and M. Fasano
Cortical Activation of Motor Areas in Parkinson’s Disease Patients
R. Moretti, P. Torre, R.M. Antonello, M. Ukmar, L. Capus, G. Cazzato and A.
Effects of Helicobacter Pylori Eradication on L-Dopa Absorption in
Parkinson’s Disease Patients
L. Brusa, A. Pietroiusti, M. Pierantozzi, S. Galati, V. Moschella, G.
Sancesario, G. Lunardi, E. Fedele, M.J. Gomez Miguel, I. Luzzi, A.
Bergamaschi, A. Magrini, P. Stanzione and A. Galante
Dystonia and Other Diskinesia in Parkinson’s Disease and Parkinsonism
A 12 Month Follow-up in Fifteen Patients with Parkinson’s Disease:
Neuropsychological Changes After Subthalamic Nucleus Stimulation
R. Moretti, P. Torre, R.M. Antonello, L. Capus, T. Cattaruzza, G. Cazzato
and A. Bava
Long-term follow-up Study with Repetitive Transcranial Magnetic
Stimulation (rTMS) in Parkinson’s Disease
J. Málly, R. Farkas, L. Tóthfalusi and T.W. Stone
Therapeutic Efficacy and Tolerability of Olanzapine in Essential Tremor
K. Bayülkem, H. Efendi and G. Karabaş
in CNS Diseases
Pharmacotherapeutical Strategies in PD-related Psychosis
The Treatment of Depression in Parkinson’s Disease
Recurrent Major Depression and Nuclear Magnetic Resonance: A Volumetric
G. Perini, F. Nifosě, T. Toffanin, S. Zanone, G. Ghelli, C. Gatto and P.
Venlafaxine Versus Sertraline in Patients with Depression in Parkinson’s
K. Bayülkem and F. Torun
Epilepsy and Headache
Monotherapy versus Polypharmacy in Epilepsy
Ih Channels and Epilepsy
R. Surges and T.J. Feuerstein
Utilization of Antiepleptic Drugs at University Department of Neurology
in Defined Daily Doses per Thousand Bed-Days During the Year 2000
M. Lisak, Z. Trkanjec, M. Nevečeral and V. Demarin
Cervicogenic Headache: Diagnostic Criteria and Clinical Picture
F. Antonaci, G. Bono, P. Chimento, A. Fanti and G. Nappi
Tension-Type Headache – Nature and Characteristics. A Personal View
Neuropathic Pain. An Overview
L. Vécsei, E.T. Varga and S. Beniczky
Human Experimental Pain Research: Assessment of Neuropathic Pain and
O.K. Andersen and L. Arendt-Nielsen
Neurovirology and CNS Disorders
Botulinum Toxin Type A in Pain Management
L. Bach-Rojecky, M. Relja and Z. Lacković
Long-Term Efficacy of Interferon-Beta and the Role of Neutralizing
Functional Status of Multiple Sclerosis Patients During Interferon Therapy
M. Bošnjak Pašić, Z. Trkanjec, M. Lisak and V. Demarin
Bone Marrow Transplantation in Adults: Impact on Cognition
P. Sostak, A. Gerbitz, H-J. Kolb, CS. Padovan and A. Straube
Is Tourette’s Syndrome an Autoimmune Disease?
P. Hoekstra, P. Limburg, C. Kallenberg and R. Minderaa
Metoclopramide Induced Parkinsonism and Mixed Polyneuropathy in a Patient
with Acute Renal Failure: A Case Report
K. Bayulkem, G. Karabaş, B. Erkal and A. Yilmaz
Kynurenic Acid Metabolism in Rat, Piglet and Human Tissues
H. Baran, B. Kepplinger, M. Draxler and H. Ferraz-Leite
KCN Influences Kynurenine Aminotransferase I and II Activities in an In
B. Kepplinger, M. Draxler, H. Ferraz-Leite, J. Wallner, H. Schmid and H.
Effectiveness of the Paroxetine in the Treatment of the Selective
Muteness in Developmental Age
L. Cenci, A. Cester, F. Costanzi, O. Papa and C. Cardinali